Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
Grabenstrasse 11A
8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, July 1st, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today is pleased to announce the submission of an application to the European Medicines Agency (EMA) to receive Orphan Drug Designation (ODD) status for its lead product TOP-N53 to treat digital ulcers in patients with systemic sclerosis.
“The submission of our ODD represents a major milestone for the Company and it brings significant benefits to the development process of TOP-N53,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “We believe that TOP-N53 has significant potential to provide a valuable treatment option for digital ulcers in patients afflicted by systemic sclerosis, a disabling condition.”
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.
Read moreTopical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
Read moreTopadur Pharma AG and Juvic Inc. Launch Transnational Collaboration for the Disease Management of Systemic Sclerosis
Read more
